Aspergillosis Pipeline Product - Research and Development 2017 Aspergillosis - Pipeline Review, H1 2017

Aspergillosis - Pipeline Review, H1 2017 provides comprehensive information on the therapeutics
under development for Aspergillosis (Infectious Disease), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
Inquire for Complete Aspergillosis Pipeline Review H1 2017 Report at
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1010786
Description of Report:
Aspergillosis (Infectious Disease) pipeline reviews key companies involved in Aspergillosis
(Infectious Disease) therapeutics development and enlists all their major and minor projects,
dormant and discontinued projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I,
Preclinical and Discovery stages are 2, 5, 19 and 2 respectively. Similarly, the Universities portfolio in
Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.
Major Companies Discussed In Report Amplyx Pharmaceuticals Inc, Astellas Pharma Inc, Biomar
Microbial Technologies, Biosergen AS, Cidara Therapeutics Inc, F2G Ltd, Hsiri Therapeutics LLC, iCo
Therapeutics Inc, Matinas BioPharma Holdings Inc, Merck & Co Inc, Nanomerics Ltd, Novabiotics Ltd,
Pulmatrix Inc, Pulmocide Ltd, Scynexis Inc, Sealife PHARMA GMBH, Sigma-Tau SpA, Vical Inc, Visterra
Inc.
Drugs Profiles Discussed In Report amphotericin B, Amphotericin B sodium, APX-001, APX-001A,
ASP-9726, Aspergillus fumigatus vaccine, BSG-005, C-001, C-016, CD-101, celastrol, Cellullar
Immunotherapy for Viral Infections and Fungal Infections, F-901318, itraconazole, KB-425796C,
MDN-0018, NP-339, PC-945, posaconazole, PTX-3, SCY-078, SLP-0901, SLP-0904, Small Molecule for
Aspergillosis, Small Molecules for Aspergillosis and Candidiasis, Small Molecules for Fungal
Infections, Small Molecules for Fungal Infections, Small Molecules for Invasive Aspergillosis, Vaccine
to Target Glucosylceramide for Fungal Infections, VIS-FNG, VL-2397
Get Discount on Report at
http://www.reportsnreports.com/contacts/discount.aspx?name=1010786 (This report is
available at up to 25% Discount till June 02 nd 2017)
Scope: The report provides a snapshot of the global therapeutic landscape of Aspergillosis. The
report reviews pipeline therapeutics for Aspergillosis by companies and universities/research
institutes based on information derived from company and industry-specific sources. The report
covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities. The report reviews key player’s involved
Aspergillosis therapeutics and enlists all their major and minor projects. The report assesses
Aspergillosis therapeutics based on drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects.